PubMed Health⌕ Search

Biomedical subjects

H C Ulutin

Publications and source records attributed to H C Ulutin.

9 recordsLinked to original sources
PubMed2003

Brachytherapy boost to the tumour bed in high risk patients after limited surgery for breast cancer.

The results of treatment for 174 patients at high risk of local recurrence, referred for radiotherapy after conservative surgery for early breast cancer, are evaluated. Microscopic margin involvement, extensive carcinoma in situ, and vascular/lymphatic invasion were the main risk factors for local recurrence. Whole-breast irradiation (40 Gy in 15 fractions over 3 weeks) followed with a brachytherapy boost (Ir192 wire implant or PDR Ir192) of 25 Gy was applied. Median follow-up was 80 months. The actuarial 6-year overall survival rate was 91% and the within breast recurrence-free survival was 88%. The most common risk factor among those recurring within the breast was involved surgical margins (13 out of 17). Cosmesis was reported to be good or excellent in 79% of cases. In patients at high risk for local recurrence, tumour-bed boost with brachytherapy can provide satisfactory local control after limited surgery and external radiotherapy.

Adult↗
PubMed2002

Postoperative radiotherapy for ganglioglioma; report of three cases and review of the literature.

Gangliogliomas are rare tumors of the central nervous system. The definite role of postoperative radiotherapy has not been established. In studying three cases who underwent radiotherapy after subtotal resection, we evaluated the clinical, pathological, radiological features with follow-up of mean 8.1 years. All of three patients were male, and mean age was 22.3 years. All of the cases have temporal lobe lesions and, except for one, they all have seizures. Radiotherapy was given to all patients after surgery. Parallely opposed local fields were used. A total of 54 Gy in 5.5 weeks was given to the mid-plane using a Co-60 tele-therapy device. No recurrence, no new symptoms, and no new neurological deficiency were detected during follow-up.

Adult↗
PubMed2002

Can radiotherapy be a treatment option for elderly women with invasive vulvar carcinoma without radical surgery?

PURPOSE OF THE INVESTIGATION: To evaluate the impact of radiotherapy after limited surgery in vulvar carcinoma. METHODS: Between March 1980 and January 2000, 22 patients older than 60 years and suffering from invasive vulvar carcinoma were treated with limited surgery and radiotherapy at Gülhane Military Medicine Academy. These are the subjects of this review. RESULTS: The median age of the patients was 67 (range 60 to 78 years). Median follow-up was 35 months (range 12 to 60 months). Local recurrence rate was 18%. Median time to local failure was 12 months (range 8 to 14 months). Two patients with local failure also developed lung metastases. Five-year survival rate was 60% and cause-specific survival rate was 69%. No treatment delay or death related to treatment was observed. CONCLUSIONS: Radiotherapy and conservative surgery can be an alternative to radical surgery with less morbidity in elderly patients.

Age Factors↗
PubMed2000

Comparison of granulocyte-colony, stimulating factor and granulocyte macrophage-colony stimulating factor in the treatment of chemotherapy extravasation ulcers.

The results of perilesional granulocyte macrophage-colony stimulating factor and granulocyte-colony stimulating factor application in a patient with chemotherapy extravasation ulcers are reported. A 64-year-old patient with recurrent ovarian carcinoma was admitted to our department in February 1999. In June 1998, six cycles of chemotherapy were applied to the patient after surgery. At the first cycle, two ulcers appeared on both lower arms related to doxorubicin extravasation despite all interventions. When the patient was admitted to in our department, we observed an ulcer on the distal part of the right lower arm with a dimension of 1.5x2 cm and another on the proximal portion of the left lower arm with a dimension of 2.5x3 cm. Of those ulcers, the bigger and deeper one on the left was treated with weekly 400 mcg granulocyte macrophage-colony stimulating factor subcutaneously for three weeks. The lesion completely disappeared in the fourth week. The other ulcer that was left for control on the right arm was treated with weekly 48 M.U. granulocyte-colony stimulating factor for four weeks. This ulcer did not reduce in size. As a result granulocyte-colony stimulating factor did not affect the healing of chemotherapy extravasation ulcers, as did granulocyte macrophage-stimulating factor.

Antineoplastic Agents↗
PubMedDate not supplied

Soft tissue sarcoma of the vulva: A clinical study.

The purpose of this study is to report clinical aspects and treatment results of patients seen at Johns Hopkins. A search of the tumor registry of the Sidney Kimmel Comprehensive Cancer Center found 453 patients with malignancies of the vulva registered between 1977 and 1997. Patient and tumor characteristics, treatment methods, and follow-up were obtained from charts. Seven patients were identified with sarcoma of the vulva. Of these, one was removed from analysis due to histology. Three patients had leiomyosarcoma, two had fibrosarcoma, and one had epithelioid sarcoma. The mean age was 41. Mean time to diagnosis was 6 months. All but one of the tumors was located on the labia majora. Median tumor size was 3.5 cm. Surgery varied from wide local excision to radical vulvectomy with inguinal lymph node dissection. Surgical margins were microscopically negative in five of the six cases. Two patients had received adjuvant external beam radiation. One of them had a tumor greater than 5 cm and close surgical margins and the other had high-grade tumor, which recurred after previous surgery. Mean follow-up was 127.8 months. There have been no recurrences to date.

Adolescent↗
PubMedDate not supplied

Split-course radiotherapy with or without concurrent or sequential chemotherapy in non-small cell lung cancer.

In our department we designed a three-armed study to compare the effects of sequential and concurrent chemoradiotherapy in locally advanced non-small cell lung cancer. Each treatment arm consisted of 15 patients with histologically confirmed stage III non-small cell lung cancer. In group 1, the main treatment approach was split-course radiotherapy alone. In group 2, 6 mg/m2 of cisplatin was applied daily and concurrently with split-course radiotherapy. In group 3, two cycles of etoposide, ifosfamide, and cisplatin chemotherapy, which ended three weeks before split-course radiotherapy, was applied. Overall response rates were 40%, 66%, and 53% in groups 1, 2, and 3, respectively. Median survival was 10, 11, and 10 months for groups 1, 2, and 3 respectively. Results are discussed in the light of the literature.

Antineoplastic Combined Chemotherapy Protocols↗
PubMedDate not supplied

Prostate specific antigen in the female body: its role in breast cancer prognosis.

Prostate-specific antigen, a 33 kDa serine protease, is found at high concentrations in seminal plasma and prostate epithelial cells. It is currently used for the diagnosis and monitoring of prostate carcinoma. However, several investigators have demonstrated nonprostatic sources of prostate specific antigen, including amniotic fluid, breast milk, breast cyst fluid, nipple aspirate fluid, and breast tumor cytosol. Studies have revealed that a high prostate-specific antigen level in tumors of women with breast cancer is associated with good prognosis. This finding is analyzed in this manuscript.

Amniotic Fluid↗
PubMedDate not supplied

Endovascular radiotherapy for stenosis after percutaneous transluminal coronary angioplasty.

The rate of restenosis after percutaneous transluminal coronary angioplasty ranges from 30% to 60%. Despite numerous trials, no effective pharmacological therapy has been found. This late effect can be reduced by endovascular radiotherapy. In animal models of restenosis after balloon injury, there is marked reduction of neointimal proliferation when the injured vessel is irradiated, using a variety of radiation sources and delivery systems. Early human trials did not focus on the importance of source selection and calibration. Other aspects which should be carefully determined are source selection and responsibilities of the treatment team. These matters are reviewed and discussed.

Angioplasty, Balloon, Coronary↗